Premium
Ionis Pharmaceuticals, (ISIS)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
CARLSBAD, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company overview...
CARLSBAD, Calif., Jan. 5 /PRNewswire/ -- Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces...
OGX-011 Phase 3 Studies in First- and Second-Line Advanced Prostate Cancer and Non-Small Cell Lung Cancer Expected to Begin in 2010 and Early 2011 CARLSBAD, Calif., Dec. 21 /PRNewswire-FirstCall/...
CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis. We believe we are at one of...
CARLSBAD, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company...
CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company...
- Conference Call Webcast Thursday, August 6, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced its...
CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), the leader in antisense therapeutics, today announced that management will present a company overview...
VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., announced the appointment of Mr. Stephen Anderson as Chief Financial Officer and Mr. Tom Bailey as a member of the Board...
VANCOUVER, Aug. 16 /PRNewswire-FirstCall/ -- OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancer, announced the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
